{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-016877","form_type":"8-K","ticker":"CTNM","cik":"0001855175","company_name":"Contineum Therapeutics, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.184108+00:00","generated_at":"2026-05-21T10:26:08.200064+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Contineum Q1 net loss $16.0M, cash $190.7M; files $300M shelf & $75M ATM","bullets":["Net loss of $16.0M vs $8.4M in Q1 2024; R&D expenses rose 76% to $13.7M.","Cash and equivalents of $190.7M; runway projected through 2027.","Files $300M universal shelf registration and $75M at-the-market (ATM) equity facility with Leerink Partners.","PIPE-791 Phase 1b PET topline data expected Q2 2025; Phase 2 initiation in IPF and PrMS planned H2 2025.","PIPE-307 Phase 2 VISTA RRMS topline data anticipated H2 2025; J&J Phase 2 MDD trial recruiting."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-016877","json":"https://secwatch.observer/filing/0001437749-25-016877.json","markdown":"https://secwatch.observer/filing/0001437749-25-016877.md","text":"https://secwatch.observer/filing/0001437749-25-016877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925016877/0001437749-25-016877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925016877/cont20250321_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T10:26:08.200064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}